Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTen-01: UB-TT170 and CAR T Cells in Osteosarcoma
NCT05312411Phase 1Active, not recruiting
- Sponsor
- Seattle Children's
- Start
- May 2022
- Primary completion
- Mar 2025
- Modality
- Bivalent/Multivalent Binders, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UB-TT170 and SCRI-E2CAR_EGFRtv1 in osteosarcoma (OS), sponsored by Seattle Children's. Primary endpoint: Adverse events associated with ex-vivo expanded autologous T cells genetically modified to express an antiFL(FITC-E2) CAR administered with UB-TT170 at 30 days. Started May 2022; status: active, not recruiting.
02
Drugs
UB-TT170SCRI-E2CAR_EGFRtv1
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT05312411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05312411.